Former FDA exec charged with securities fraud, along with two hedge fund managers

A shocking case of insider trading has rocked the drug development world and beyond. Earlier this month, a former Food and Drug Administration (FDA) official and two hedge fund managers were indicted for insider trading that made them unlawful profits of about $32 million. On June 15, the Securities and Exchange Commission (SEC) charged the men with using inside information to buy stocks from com­panies that were soon to have generic drugs approved, with the former FDA official gleaning tips from friends still working at the FDA. Ac­cording to the U.S. attorney’s office in New York, the three men colluded from 2005 to 2011.

Bioclinica debuts new divisions to support patient engagement

In a strategy to address the industry-wide challenges of patient engagement in clini­cal trials, the specialty services provider Bioclinica has announced the creation of two separate divisions, a Research Network and Patient Recruitment-Retention, under the company’s Global Clinical Research business segment.

To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.